Discover the implications of the FSCA's R358.75 million fine on former Steinhoff executive Stehan Grobler, as South Africa grapples with the fallout from one of its largest corporate scandals
The majority of investors see another year of positive returns ahead in 2026, with almost no one expecting a correction.
Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) margins increased by 29 bps to 16.0% in the fourth quarter of 2025 as compared with 15.7% in the fourth quarter of 2024Adjusting for unusual or one-time items impacting Net Income in the quarter, Adjusted Earnings Per Share(3) was $0.23 for the fourth quarter of 2025; This compares with Adjusted Earnings Per Share(3) of $0.24 for the fourth quarter of 2024 In the fourth quarter of 2025, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 14.1% and same-center advanced imaging procedural volumes increased 9.6% as compared with the fourth quarter of 2024RadNet releases 2026 guidance levels which anticipate Imaging Center segment Revenue growth of 17%-19%, Adjusted EBITDA(1) growth of 18%-22% and Free Cash Flow(2) growth of 29%-41% from 2025 levels; 2026 guidance levels anticipate Digital Health Revenue growth of 46%-56%LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 418 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full-year ended December 31, 2025.Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "I am very pleased with the fourth quarter performance. Relative to last year's fourth quarter, Total Company Revenue increased 14.8% and Adjusted EBITDA(1) increased 16.9%, resulting in margin improvement of 29 basis points. This performance was driven by strong aggregate and same center procedural growth, combined with a continued focus on driving operating and clinical efficiencies within the Imaging Center segment. These factors, amongst others, contributed to RadNet exceeding 2025 Revenue and Adjusted EBITDA(1) guidance levels in the Imaging Center segment, which had been amended upwards throughout the year."Dr. Berger continued, "During the fourth quarter, we continued to experience increasing demand for our services in virtually all core markets, and operations teams were focused on improving patient-throughput and driving capacity at existing centers. In particular, disproportionately higher demand for advanced imaging continues to benefit our procedure mix, evidenced by a 178 basis point increase in MR, CT and PET/CT as a percentage of our overall procedure volume when compared with the fourth quarter of last year. At the same time, during the fourth quarter and throughout 2025, significant investments were made to open new centers and complete tuck-in acquisitions within virtually all core RadNet markets. RadNet centers continue to implement DeepHealth technology solutions to drive efficiencies, lower costs and automate manual processes. This includes the comprehensive roll-out of TechliveTM, See-Mode and other clinical and workflow tools designed to increase productivity, create capacity and decrease exposure to the challenging labor market. In the coming quarters, as we continue to implement many of these solutions internally, we will have the opportunity to demonstrate the power of improved automation and more advanced clinical and operational capabilities, which we believe will lead to more favorable patient care and health outcomes, improved service levels to referring physicians, further alignment with health system partners and closer relationships with insurance plans and other payors.""Moving into 2026, RadNet is well-positioned to accelerate growth within Digital Health. With the addition of products resulting from this morning's acquisition of Gleamer in Paris, France, the Digital Health division now includes what we believe to be the most comprehensive and broad collection of clinical AI solutions of any company worldwide. This will have broad implications for the performance of RadNet's core Imaging Center business, the businesses of the over 2,700 current Digital Health customers and future customers throughout the diagnostic imaging industry. The diagnostic imaging industry will transform in the coming years as a result of an industry-wide adoption of the kind of AI-powered workflow and clinical tools that RadNet is acquiring, developing, utilizing and commercializing. We intend to continue to develop and bring-to-market solutions that address the critical challenges the industry faces, including labor shortages, capacity constraints and the inability of radiologists to keep pace with growing industry volumes, all in an effort to improve patient care and outcomes," concluded Dr. Berger.Financial ResultsFourth Quarter Report:For the fourth quarter of 2025, RadNet reported Total Company Revenue of $547.7 million and Adjusted EBITDA(1) of $87.7 million. Revenue increased $70.6 million (or 14.8%) and Adjusted EBITDA(1) increased $12.7 million (or 16.9%) as compared with the fourth quarter of 2024. For the fourth quarter of 2025, RadNet reported Digital Health Revenue of $27.9 million (inclusive of intersegment revenue) and Adjusted EBITDA(1) of $4.9 million. Revenue increased $9.1 million (or 48.2%) and Adjusted EBITDA(1) increased $0.4 million (or 8.9%) as compared with the fourth quarter of 2024.There were a number of unusual or one-time items impacting the fourth quarter including: $531,000 in severance expense related to cost-savings initiatives; $233,000 impairment loss on lease abandonment; $788,000 expense related to leases for de novo facilities under construction that have yet to open their operations; $2.3 million of acquisition transaction costs; $6.5 million loss on sale and disposal of equipment; $6.3 million of non-capitalized research and development expenses related to the DeepHealth products; $679,000 of non-cash loss from interest rate swaps; and $5.7 million adjustment to the tax provision to normalize nonrecurring and prior year tax adjustments. Adjusting for the above items, Total Company Adjusted Earnings(3) was $18.1 million and diluted Adjusted Earnings Per Share(3) was $0.23 during the fourth quarter of 2025. This compares with Total Company Adjusted Earnings(3) of $18.1 million and diluted Adjusted Earnings Per Share(3) of $0.24 during the fourth quarter of 2024.Unadjusted for unusual or one-time items impacting the fourth quarter, Total Company Net Loss for the fourth quarter of 2025 was $0.6 million as compared with a Total Company Net Income of $5.3 million for the fourth quarter of 2024. Fully diluted Net Loss Per Share for the fourth quarter of 2025 was $(0.01), compared with a fully diluted Net Income per share of $0.07 in the fourth quarter of 2024, based upon a weighted average number of diluted shares outstanding of 76.6 million shares in 2025 and 75.5 million shares in 2024.For the fourth quarter of 2025, as compared with the prior year's fourth quarter, MRI volume increased 15.8%, CT volume increased 10.3% and PET/CT volume increased 28.3%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 7.0% over the prior year's fourth quarter. On a same-center basis, including only those centers which were part of RadNet for both the fourth quarters of 2025 and 2024, MRI volume increased 11.4%, CT volume increased 6.3% and PET/CT volume increased 14.3%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 4.5% over the prior year's same quarter.Annual Report:For full-year 2025, RadNet reported Total Company Revenue of $2,040.2 million and Adjusted EBITDA(1) of $300.2 million. Revenue increased $210.5 million (or 11.5%) and Adjusted EBITDA(1) increased $20.8 million (or 7.4%) as compared with full-year 2024. For full-year 2025, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $92.7 million and Adjusted EBITDA(1) of $15.5 million. Revenue increased $27.0 million (or 41.1%) and Adjusted EBITDA(1) increased $0.3 million (or 1.9%) as compared with full-year 2024. At December 31, 2025, Annual Recurring Revenue(4) (ARR) for the Digital Health was $75.4 million, representing 81.3% of 2025 Revenue.Unadjusted for one-time or unusual items, Total Company Net Loss for 2025 was $18.7 million as compared with a Total Company Net Income of $2.8 million in 2024. Fully diluted Net Loss Per Share for 2025 was $(0.25), compared with a Net Income per share of $0.04 in 2024, based upon a weighted average number of diluted shares outstanding of 75.2 million shares in 2025 and 74.8 million shares in 2024.Actual 2025 Results vs. 2025 GuidanceImaging Center Segment Original Guidance Range Revised Guidance Range After Q1 Results Revised Guidance Range After Q2 Results Revised Guidance Range After Q3 Results Actual 2025 Results Total Net Revenue$1,825-$1,875mm $1,835-$1,885mm $1,850-$1,900mm $1,900-$1,930mm $1,988.2mmAdjusted EBITDA(1)$265 - $273mm $268 - $276mm $271 - $279mm $276 - $284mm $284.7mmCapital Expenditures(a)$140 - $150mm $145 - $155mm $152 - $162mm $157 - $167mm $170.5mmCash Interest Expense(b)$35 - $40mm $35 - $40mm $35 - $40mm $31 - $36mm $32.5mmFree Cash Flow (2)$70 - $80mm $70 - $80mm $70 - $80mm $70 - $80mm $81.7mm (a) Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.(b) Net of payments received from counterparties on interest rate swaps and interest income from our cash balance recorded in Other Income.Digital Health Segment Original Guidance Range Revised Guidance Range After Q2 Results Revised Guidance Range After Q3 Results Actual 2024 Results Total Net Revenue (inclusive of intersegment revenue)$80 - $90mm $80 - $90mm $85 - $95mm $92.7mm Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$15 - $17mm $15 - $17mm $15 - $17mm $15.5mm Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$16 - $18mm $17 - $19mm $18 - $20mm $20.2mm Capital Expenditures(a)$3 - $5mm $2 - $4mm $3 - $5mm $2.0mm Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$11 - $13mm $11 - $13mm $10 - $12mm $13.5mm Free Cash Flow(2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(5) - $(8)mm $(5) - $(8)mm $(5) - $(9)mm $(6.7)mm (a) Excludes a $2.6 million purchase of software code and other intellectual property.2026 GuidanceRadNet reports 2026 guidance ranges as follows: Imaging Center Segment 2026Guidance Range Total Net Revenue$2,325 - $2,375Adjusted EBITDA(1)$335 - $348 millionCapital Expenditures(a)$165 - $175 millionCash Interest Expense(b)$45 - $50 millionFree Cash Flow(2)$105 - $115 million (a) Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.(b) Net of payments from counterparties on interest rate swaps and interest income earned from our cash balance recorded in Other Income.Dr Berger added, "Within the Imaging Center segment, we expect 2026 performance to benefit from the contribution of continued increases in same-center performance, further tuck-in acquisitions, reimbursement efforts driving more favorable pricing and de novo center openings. As a result, our guidance implies 2026 Revenue to grow 17%-19%, Adjusted EBITDA(1) to grow 18%-22% and Free Cash Flow(2) to grow 29%-41% as compared with 2025 full year performance. We are anticipating this strong growth despite headwinds embedded in the guidance levels from projected increases in same-center labor costs as well as the recent impact of severe winter weather conditions experienced in January and February."Digital Health Segment 2026Guidance Range Total Net Revenue(a)$135 - $145 million Adjusted EBITDA(1) Before Non-Capitalized R&D(b)$10 - $12 million Non-Capitalized R&D$17 - $19 million Capital Expenditures$9 - $12 million Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(1) - $3 million Free Cash Flow(2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(17) - $(19) million (a) Includes approximately $16 million of Revenue as a result of the acquisition of Gleamer SAS announced this morning.(b) Includes a loss of approximately $5 million of Adjusted EBITDA(1) Before Non-Capitalized R&D as a result of the acquisition of Gleamer SAS announced this morning."Within the Digital Health segment, 2026 growth will be driven by sales of the DeepHealth portfolio of AI-powered workflow and clinical solutions and related products such as TechLiveTM and further contribution from the acquisitions of iCAD, See-Mode, CIMAR and Gleamer. We are anticipating a minimum of four FDA clearances during 2026, further advancing our leadership in radiology clinical AI solutions in the areas of mammography, lung, prostate, thyroid, brain and, with this morning's announced acquisition of Gleamer, the musculoskeletal system. In 2026, significant infrastructure investments will continue to be made in building sales, marketing and implementation teams to support future growth. Despite the continued focus it takes to invest in building the infrastructure of the business, 2026 Digital Health guidance implies growth of Revenue between 45% and 55% from 2025 full-year performance. We anticipate ARR at December 31, 2026 to approach or exceed $140 million. Furthermore, we expect that the proportion of Digital Health's Revenue coming from RadNet's Imaging Center segment will decline from approximately 45% in 2025 to about 33% in 2026," concluded Dr. Berger.Conference Call TodayDr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, March 2nd, at 10:30 a.m. Eastern Time. During the call, management will discuss the Company's 2025 fourth quarter and year-end results.Conference Call Details:Date: Monday, March 2, 2026Time: 10:30 a.m. ETDial In-Number: 844-826-3035International Dial-In Number: 412-317-5195There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1753363&tp_key=503d78aa96 [viavid.webcasts.com] or http://www.radnet.com under the "About RadNet" menu section and "News & Press Releases" sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10206844.About RadNet, Inc.RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at www.radnet.com.Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements in this press release include statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:changes in general economic conditions nationally and regionally in the markets in which we operate, including their effects on the cost and availability of labor;our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;volatility in interest and exchange rates, or credit markets;the adequacy of our cash flow and earnings to fund our current and future operations;changes in service mix, revenue mix and procedure volumes;delays in receiving payments for services provided;increased bankruptcies among our partner physicians or joint venture partners;the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities;the occurrence of hostilities, political instability or catastrophic events;the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; andnoncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.Regulation G: GAAP and Non-GAAP Financial InformationThis release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.CONTACTS: RadNet, Inc.Mark Stolper, 310-445-2800Executive Vice President and Chief Financial Officer RADNET, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) December 31, 2025 December 31, 2024 ASSETS CURRENT ASSETS Cash and Cash equivalents$767,215 $740,020 Accounts receivable 200,317 185,821 Due from affiliates 12,592 41,869 Prepaid expenses and other current assets 52,003 51,542 Total current assets 1,032,127 1,019,252 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property and equipment, net 807,702 694,791 Operating lease right-of-use assets 690,250 639,740 Total property, plant, equipment and right-of-use assets 1,497,952 1,334,531 OTHER ASSETS Goodwill 907,663 710,663 Other intangible assets 148,508 81,351 Deferred financing costs 1,684 2,265 Investment in joint ventures 130,340 104,057 Deposits and other 40,289 34,571 Total Assets$3,758,563 $3,286,690 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other$422,029 $351,464 Due to affiliates 70,104 43,650 Deferred revenue 7,272 3,288 Current operating lease liability 61,934 56,618 Current portion of notes payable 25,424 24,692 Total current liabilities 586,763 479,712 LONG-TERM LIABILITIES Long-term operating lease liability 707,001 655,979 Notes payable, net of current portion 1,064,495 991,574 Deferred tax liability, net 21,903 22,230 Other non-current liabilities 22,515 3,785 Total liabilities 2,402,677 2,153,280 EQUITY RadNet, Inc. stockholders' equity: Common stock - $0.0001 value, 200,000,000 shares authorized; 77,399,615 and 74,036,993 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively 8 7 Additional paid-in-capital 1,180,434 988,147 Accumulated other comprehensive loss 4,885 (9,061)Accumulated deficit (95,437) (76,785)Total RadNet, Inc.'s Stockholders' equity: 1,089,890 902,308 Noncontrolling interests 265,996 231,102 Total Equity 1,355,886 1,133,410 Total liabilities and equity$3,758,563 $3,286,690 RADNET, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENT OF OPERATIONS(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA) Years Ended December 31, 2025 2024 2023 REVENUE Service fee revenue$1,914,673 $1,693,089 $1,463,197 Revenue under capitation arrangements 125,537 136,575 153,433 Total service revenue 2,040,210 1,829,664 1,616,630 OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 1,804,725 1,580,549 1,395,239 Lease abandonment charges 8,563 2,478 5,146 Depreciation and amortization 152,127 137,838 128,391 Loss ...Full story available on Benzinga.com
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a summary of recent business highlights.
TORONTO, March 02, 2026 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay”) (TSX, NYSE: HBM) and Arizona Sonoran Copper Company Inc. (“ASCU”) (TSX: ASCU; OTCQX: ASCUF) are pleased to announce that they have entered into a definitive agreement (the “Arrangement Agreement”) pursuant to which Hudbay has agreed to acquire all of the issued and outstanding common shares of ASCU, not already owned by Hudbay, for consideration of 0.242 of a common share of Hudbay per common share of ASCU (the “Transaction”). The offer implies a value of C$9.35 per ASCU share based on Hudbay's closing share price on the Toronto Stock Exchange (“TSX”) on February 27, 2026, and represents a premium of 30% to ASCU’s closing share price on February 27, 2026. The offer implies a premium of 36% based on Hudbay’s and ASCU’s 20-day volume-weighted-average share prices ("VWAP") on the TSX for the period ending February 27, 2026. The Transaction will result in Hudbay owning a 100% interest in ASCU’s Cactus project (“Cactus”).
TORONTO, March 02, 2026 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) to acquire, through a wholly-owned subsidiary, Glencore Canada Corporation’s (“Glencore”) 100% interest in the Kidd operations (“Kidd” or the “Kidd Operations”) in Timmins, Ontario (the “Transaction”). The Kidd Operations include the Kidd Metallurgical Site (the “Kidd Met Site”), the Kidd tailings management area (the “Kidd TMA” or the “TMA”) and the Kidd Creek copper, zinc and silver mine (the “Kidd Creek Mine”). All amounts are in US dollars unless otherwise specified.
Rising oil prices, a weaker rand and inflation risks could weigh on South Africa’s fragile recovery.
K92 announces 2025 financial results - record net cash balance, revenue, net earnings, cash flow and EBIDTA, production, cash costs, AISC below guidance
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/TORONTO, March 2, 2026 /CNW/ - Arizona Metals Corp. (TSX:AMC) (OTCQX:AZMCF) (the "Company" or "Arizona Metals") is pleased to announce the third and final round of results from its 2025 reverse-circulation drill program on the Company's Sugarloaf Peak Gold Project (the "Sugarloaf Peak Project") in Arizona, which returned the highest gold grade on the project to date. Consistent with previous results from the Company's 2025 drill program, these final drill results expand the deposit and they confirm excellent continuity of mineralization within an increasingly large gold deposit. Highlights of the drilling include:SP-25-28: 91.4 m @ 0.69 g/t Au, including 1.5 m @ 25.5 g/t Au, the highest gold grade on the property to date (including surface samples). This hole, along with hole 29, extended mineralization approximately 80 m to the south in a previously undrilled area (Figure 1). Hole 28 also intersected 57.9 m @ 0.29 g/t Au and 18.3 m @ 0.39 g/t Au (Table 1).SP-25-29: 123.4 m @ 0.31 g/t Au. This hole intersected a large thickness of mineralization starting at surface in a previously untested area on the southern margin of the deposit. Holes 29 and 28 (collared at the same location) show outstanding potential for continued expansion of the deposit laterally to the south/southwest and along strike to the southeast.SP-25-26: 56.4 m @ 0.43 g/t Au. Hole 26 tested a 270 x 340 m gap in the eastern end of the deposit and intersected thick mineralization, reinforcing the excellent continuity of mineralization at Sugarloaf Peak.All six of the final drill holes intersected mineralization, growing the deposit laterally and reinforcing the strong continuity of mineralization on the project. The total drilling to date on the project, in 2025 and 2026, comprises 5,186 m drilled in 25 reverse-circulation drill holes.Duncan Middlemiss, President and CEO of Arizona Metals commented: "We are very encouraged with these results from our 2025 drill program at Sugarloaf Peak. This has been the most successful drill campaign on the project to date, intersecting mineralization in 22 out of 25 holes, and showing significant expansion upside and excellent continuity of an already large gold deposit that crops out at surface. The Company's drilling shows Sugarloaf to be a robust gold deposit, and we look forward to further developing its value."Additional drill results are as follows:SP-25-24: 24.4 m @ 0.23 g/t Au and 30.5 m @ 0.32 g/t Au. This is an infill hole in a 225 x 475-m gap in the northwestern part of the deposit. SP-25-27: 51.8 m @ 0.30 g/t Au and 27.4 m @ 0.34 g/t Au. Hole 27 intersected thick mineralization in a 340 x 360-m gap in the eastern end of the deposit.The Company is currently conducting a comprehensive exploration synthesis consisting of 990 surface rock samples for multi-element geochemistry; IP-resistivity geophysics and airborne magnetic and radiometric geophysics; an airborne hyperspectral survey; geologic reviews of previous mapping, drill core, and drill cuttings; AI targeting studies; and a thorough integration of historical data. The intent of this exploration program is to integrate new modern geochemical, geophysical, and geologic data with historical data in order to comprehensively target drilling for expanded deposit size and higher gold grades.Table 1. Results of the drill program at the Sugarloaf Peak Project, La Paz County, Arizona, announced in this news release, including the depth of oxidized mineralization encountered in each hole.The true width of mineralization has not been determined at this time.Full story available on Benzinga.com
As fears of mass unemployment grow, three leading economists advocate some policies to shift the focus from job displacement to job enhancement.
Dollar index: Rupee sinks 42 paise to 91.50 against the US dollar as Iran strikes trigger risk aversion, FII outflows and a surge in Brent crude. Sensex and Nifty tumble, while RBI intervention caps further losses in the forex market.
Hong Kong and Shanghai have signed an accord deepening their collaboration in promoting digitised cargo trade finance and strengthening mainland China’s connection to the global data ecosystem.The Hong Kong Monetary Authority (HKMA) on Monday signed a memorandum of understanding (MOU) with the Shanghai Data Bureau and the National Technology Innovation Centre for Blockchain, according to a statement from Hong Kong’s de facto central bank.“This marks an important milestone in the collaboration...